---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059508"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:09:58.280014+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioAtla Q1 net loss $23.2M, cash $80.6M; positive Phase 2 data for ozuriftamab vedotin and evalstotug

## Summary
- Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.
- Ozuriftamab vedotin in SCCHN: 11 total responses (5 confirmed incl. 1 CR), 86% DCR; FDA meeting for potential registrational trial expected 2H 2024.
- Evalstotug: DLT clearance at 1 gram in 2Q 2024; Phase 2 monotherapy data 2Q 2024; FDA meeting for BRAF-mutated melanoma registrational trial in 2H 2024.
- Mecbotamab vedotin in UPS: initial 20 patients enrolled; FDA meeting for remaining trial portion 2H 2024.
- CAB-Nectin4-ADC (BA3361) received FDA IND clearance in May 2024.

## SEC filing metadata
- accession: 0000950170-24-059508
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/0000950170-24-059508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/bcab-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059508
- JSON: https://secwatch.observer/filing/0000950170-24-059508.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059508.txt

## Key facts
- Earnings Releases
  BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000095017024059508/0000950170-24-059508-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.